Canis ISSN: 2398-2942

Oclacitinib

Synonym(s): Apoquel®.

Contributor(s): David Godfrey, Linda Horspool

Introduction

Name

  • Oclacitinib, Apoquel®.

Class of drug

  • Immunosuppressant.
  • Agents for dermatitis, excluding corticosteroids.
  • Synthetic Janus kinase (JAK) inhibitor.

Description

Chemical name

  • N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl] methanesulfonamide.

Molecular formula

  • C19H27N5O6S.

Molecular weight

  • 453.51.

Physical properties

  • Film-coated tablets containing oclacitinib maleate.
  • White to off-white, oblong shaped film-coated tablets with a score-line on both sides and marked with the letters "AQ" and "S", "M" or "L" on both sides, which refer to the different strengths of tablets: "S" 3.6 mg, "M" 5.4 mg, and "L" 16 mg tablets.
  • The tablets can be divided into equal halves.

Storage requirements

  • Shelf life as packaged for sale: 2 years.
  • Store below 25 °C.
  • Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton.
  • Any remaining half tablets should be discarded after 3 days.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Adequate serological response to vaccination with modified live canine parvovirus (CPV) and canine distemper virus (CDV) in puppies administered oclacitinib at 1.8 mg/kg twice daily for 84 days.
  • Reduced serological response to vaccination with modified live canine parainfluenza virus (CPi) and inactivated rabies virus in puppies administered oclacitinib at 1.8 mg/kg twice daily for 84 days compared to untreated controls. The clinical relevance of these observed effects for vaccination of dogs on oclacitanib treatment is unclear.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromVetMed ResourceandPubMed.
  • Collard W T, Hummel B D, Fielder A F, King V L, Boucher J F, Mullins M A, Malpas P B, Stegemann M R (2014)The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog.J Vet Pharmacol Ther37(3), 279-285PubMed.
  • Gonzales A J, Bowman J W, Fici G J, Zhang M, Mann D W, Mitton-Fry M (2014)Oclacitinib (APOQUEL(®) ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.J Vet Pharmacol Ther37(4), 317-324PubMed.
  • Cosgrove S B, Wren J A, Cleaver D M, Martin D D, Walsh K F, Harfst J A, Follis S L, King V L, Boucher J F, Stegemann M R (2013)Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.Vet Dermatol24(5), 479-e114PubMed.
  • Cosgrove S B, Wren J A, Cleaver D M, Walsh K F, Follis S I, King V I, Tena J K, Stegemann M R (2013)A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.Vet Dermatol24(6), pp. 587-597PubMed.

Other sources of information


ADDED